Literature DB >> 421236

Reduction of daunorubicin lethality and myocardial cellular alterations by pretreatment with ICRF-187 in Syrian golden hamsters.

E Herman, B Ardalan, C Bier, V Waravdekar, S Krop.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 421236

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


× No keyword cloud information.
  11 in total

1.  Pretreatment with ICRF-187 provides long-lasting protection against chronic daunorubicin cardiotoxicity in rabbits.

Authors:  E H Herman; V J Ferrans
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

2.  Phase I clinical trial and pharmacokinetics of weekly ICRF-187 (NSC 169780) infusion in patients with solid tumors.

Authors:  C L Vogel; E Gorowski; E Davila; M Eisenberger; J Kosinski; R P Agarwal; N Savaraj
Journal:  Invest New Drugs       Date:  1987       Impact factor: 3.850

Review 3.  The role of antioxidants in the era of cardio‑oncology.

Authors:  Duncan T Vincent; Yasmine F Ibrahim; Michael Graham Espey; Yuichiro J Suzuki
Journal:  Cancer Chemother Pharmacol       Date:  2013-12       Impact factor: 3.333

Review 4.  In Vivo Murine Models of Cardiotoxicity Due to Anticancer Drugs: Challenges and Opportunities for Clinical Translation.

Authors:  Serena L'Abbate; Michela Chianca; Iacopo Fabiani; Annamaria Del Franco; Alberto Giannoni; Giuseppe Vergaro; Chrysanthos Grigoratos; Claudia Kusmic; Claudio Passino; Yuri D'Alessandra; Silvia Burchielli; Michele Emdin; Daniela Maria Cardinale
Journal:  J Cardiovasc Transl Res       Date:  2022-03-21       Impact factor: 4.132

5.  Reduction of chronic doxorubicin cardiotoxicity in beagle dogs by bis-morpholinomethyl derivative of razoxane (ICRF-159).

Authors:  E H Herman; V J Ferrans; H B Bhat; D T Witiak
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

6.  Timing of treatment with ICRF-187 and its effect on chronic doxorubicin cardiotoxicity.

Authors:  E H Herman; V J Ferrans
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

7.  Cardioprotection and Safety of Dexrazoxane in Patients Treated for Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Advanced-Stage Lymphoblastic Non-Hodgkin Lymphoma: A Report of the Children's Oncology Group Randomized Trial Pediatric Oncology Group 9404.

Authors:  Barbara L Asselin; Meenakshi Devidas; Lu Chen; Vivian I Franco; Jeanette Pullen; Michael J Borowitz; Robert E Hutchison; Yaddanapudi Ravindranath; Saro H Armenian; Bruce M Camitta; Steven E Lipshultz
Journal:  J Clin Oncol       Date:  2015-12-23       Impact factor: 44.544

8.  Cardioprotection with ICRF-187 (Cardioxane) in patients with advanced breast cancer having cardiac risk factors for doxorubicin cardiotoxicity, treated with the FDC regimen.

Authors:  S Jelić; S Radulović; Z Nesković-Konstantinović; M Kreacić; Z Ristović; S Bosnjak; N Milanović; L Vuletić
Journal:  Support Care Cancer       Date:  1995-05       Impact factor: 3.603

Review 9.  Doxorubicin (adriamycin) cardiomyopathy.

Authors:  E Saltiel; W McGuire
Journal:  West J Med       Date:  1983-09

Review 10.  Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection.

Authors:  Martin Stěrba; Olga Popelová; Anna Vávrová; Eduard Jirkovský; Petra Kovaříková; Vladimír Geršl; Tomáš Simůnek
Journal:  Antioxid Redox Signal       Date:  2012-10-12       Impact factor: 8.401
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.